Related Experiment Video

Updated: Dec 30, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.9K

Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?

Susana Ravassa1, Javier Beaumont1, Germán Cediel2

  • 1Programa de Enfermedades Cardiovasculares, CIMA Universidad de Navarra, Pamplona, Navarra, Spain; Área de Enfermedades Cardiovasculares, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Navarra, Spain; Instituto de Salud Carlos III, CIBERCV, Madrid, Spain.

Revista Espanola De Cardiologia (English Ed.)
|January 18, 2020
PubMed

Insights

High insulin-like growth factor binding protein 2 (IGFBP2) levels predict cardiovascular death in heart failure (HF) patients, especially those with chronic kidney disease (CKD). CKD modifies IGFBP2

Area of Science:

  • Cardiology
  • Nephrology
  • Biomarkers

Background:

  • Elevated insulin-like growth factor binding protein 2 (IGFBP2) is linked to mortality in heart failure (HF).
  • Chronic kidney disease (CKD) increases mortality risk in HF patients.
  • IGFBP2 levels are often higher in patients with CKD.

Purpose of the Study:

  • To investigate the association between IGFBP2 and CKD in HF patients.
  • To determine if CKD modifies the prognostic value of IGFBP2 in HF patients.

Main Methods:

  • 686 HF patients were enrolled and followed for a median of 3.5 years.
  • Patients were categorized by estimated glomerular filtration rate (eGFR <60mL/min/1.73 m² for decreased eGFR).
  • Serum IGFBP2 levels were measured using ELISA.

Main Results:

  • IGFBP2 levels were significantly higher in HF patients with decreased eGFR.
  • IGFBP2 was independently associated with NT-proBNP and inversely with eGFR.
  • IGFBP2 independently predicted cardiovascular and all-cause death, with a stronger association in HF patients with decreased eGFR.

Conclusions:

  • Serum IGFBP2 is associated with impaired renal function in HF patients.
  • IGFBP2 levels predict cardiovascular death in HF patients with decreased eGFR.
  • CKD modifies the association between IGFBP2 and cardiovascular mortality in HF patients.
Abstract

Keywords:
Cardiovascular deathChronic kidney diseaseEnfermedad renal crónicaHeart failureIGFBP2Insuficiencia cardiacaMuerte cardiovascular

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.3K
Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion08:22

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion

Published on: March 20, 2017

9.1K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
844
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
171
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
607
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
746
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
697
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K